Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.

Buprenorphine discontinuation ups risk of overdose, acute care service use

26 Dec 2019

Regardless of treatment duration, discontinuation of long-term buprenorphine heightens the risk of acute care service use and overdose in adults with opioid use disorder, reports a study.

“Although buprenorphine treatment reduces risk of overdose and death in opioid use disorder, most patients discontinue treatment within a few weeks or months,” the investigators said.

This retrospective longitudinal cohort analysis used the MarketScan multistate Medicaid claims database (2013–2017), covering 12 million beneficiaries annually. Adults (aged 18–64 years) who received buprenorphine continuously for ≥180 days by cohorts retained for 6–9 months, 9–12 months, 12–15 months and 15–18 months were included.

Assessment of outcome in the postdiscontinuation period required patients to be continuously enrolled in Medicaid for 6 months following buprenorphine cessation. Primary adverse outcomes were as follows: all-cause emergency department (ED) visits, all-cause inpatient hospitalizations, opioid prescriptions and drug overdose (opioid or nonopioid).

Adverse events were common across all cohorts. Nearly half of the patients (42.1–49.9 percent) visited the ED at least once.

Patients retained on buprenorphine for 15–18 months (n=931) vs 6–9 months (n=4,126) had a significantly lower likelihood of visiting the ED (odds ratio [OR], 0.75, 95 percent confidence interval [CI], 0.65–0.86), filling opioid prescriptions (OR, 0.67, 95 percent CI, 0.56–0.80) and inpatient hospitalizations (OR, 0.79, 95 percent CI, 0.64–0.99) in the 6 months following discontinuation.

Across all cohorts, about 5 percent of patients had one or more medically treated overdoses.

“Superior outcomes became significant with treatment duration beyond 15 months, although rates of the primary adverse outcomes remained high,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.